Long non-coding RNAs (lncRNAs) emerge as important regulators of various biological processes. Many lncRNAs with tumor-suppressor or oncogenic functions in cancer have been discovered. While many studies have exploited public resources such as RNA-Seq data in The Cancer Genome Atlas (TCGA) to study lncRNAs in cancer, it is crucial to choose the optimal method for accurate expression quantification of lncRNAs. In this benchmarking study, we compared the performance of pseudoalignment methods Kallisto and Salmon, and alignmentbased methods HTSeq, featureCounts, and RSEM, in lncRNA quantification, by applying them to a simulated RNA-Seq dataset and a pan-cancer RNA-Seq dataset from TCGA. We observed that full transcriptome annotation, including both protein coding and noncoding RNAs, greatly improves the specificity of lncRNA expression quantification. Pseudoalignment-based methods detect more lncRNAs than alignment-based methods and correlate highly with simulated ground truth. On the contrary, alignment-based methods tend to underestimate lncRNA expression or even fail to capture lncRNA signal in the ground truth. These underestimated genes include cancer-relevant lncRNAs such as TERC and ZEB2-AS1. Overall, 10-16% of lncRNAs can be detected in the samples, with antisense and lincRNAs the two most abundant categories. A higher proportion of antisense RNAs are detected than lincRNAs. Moreover, among the expressed lncRNAs, more antisense RNAs are discordant from ground truth than lincRNAs when measured by alignment-based methods, indicating that antisense RNAs are more susceptible to mis-quantification. In addition, the lncRNAs with fewer transcripts, less than three exons, and lower sequence uniqueness tend to be more discordant. In summary, pseudoalignment methods Kallisto or Salmon in combination with the full transcriptome annotation is our recommended strategy for RNA-Seq analysis for lncRNAs.
INTRODUCTION
Long non-coding RNAs (lncRNAs) are a diverse class of RNA molecules that are more than 200 nucleotides in length and do not encode proteins [1] . While functional classification is lacking for most lncRNAs, based on their genomic proximity to protein-coding genes and the direction of transcription, lncRNA are often classified into antisense, intronic, bidirectional, intergenic, or overlapping RNAs [1] . GENCODE, the database that provides the largest set of standardized lncRNA annotations, defines over 15,000 human lncRNA genes in the current release (release 27, https://www.gencodegenes.org). Compared with protein-coding genes, lncRNAs are shorter, lower-expressed, less evolutionarily conserved, and expressed in a more tissue-specific manner [2] . lncRNAs have recently emerged as an essential class of regulatory elements for many biological processes including imprinting, cell differentiation, and development [3] . They are often disrupted in human diseases including cancer [4] . They may interact with DNA, RNA, and proteins, and exert regulatory roles through a variety of mechanisms. Based on their molecular functions, lncRNA may act as i) signals, which are indicators of transcriptional activity; ii) decoys, which bind to and titrate away protein targets such as transcription factors; iii) guides, which direct regulatory complexes or transcription factors to specific targets and regulate gene expression in cis or trans, and iv) scaffolds, which serve as central platforms where relevant molecular components in cells are assembled [5] .
lncRNAs have been shown to be important in the pathogenesis of human diseases, especially in cancer, and many cancer-relevant lncRNAs have been identified [6, 7] . For example, Hox transcript antisense RNA (HOTAIR), one of the most well-characterized lncRNAs, promotes breast cancer metastasis through recruitment of Polycomb chromatin remodeling complex to silence the HOXD gene cluster [8] . HOTAIR is overexpressed in breast, liver, pancreatic, lung, and pancreatic cancers [9] . CDKN2B-AS1, an antisense lncRNA encoded by the CDKN2B locus, epigenetically silences nearby tumor suppresser genes and promotes oncogenesis. [10] .
Telomerase RNA component (TERC), the critical RNA component of telomerase polymerase, serves as a template for the enzyme telomerase reverse transcriptase (TERT) to elongate telomeres. Variants and copy-number changes at the TERC locus have been associated with cancer risk and progression [6] . The lincRNA MEG3 inhibits cell proliferation by downregulating MDM2 and promoting p53 accumulation [11] .
Discovery of oncogenic and tumor suppressor lncRNAs has led to an increased interest in investigation of lncRNAs as potential cancer drug targets and biomarkers. Hence, it is critical to accurately determine lncRNA expression in cancer research. RNA sequencing (RNA-Seq) has been widely used for massive-parallel gene expression quantification. Many lncRNAs are transcribed by RNA polymerase II and are often 5ʹ-capped, spliced and polyadenylated [12] . In a study of an earlier GENCODE version, it was estimated that 39% of lncRNAs contains poly(A) motifs, compared to 51% for protein-coding transcripts [2] . Thus, although RNA-Seq was originally designed to inspect protein-coding genes expression, a significant proportion of lncRNAs can also be examined within RNA-Seq data derived from samples that have been prepared even using poly (A) enrichment method. Multiple tools for processing RNA-Seq data have been developed in recent years. While some studies have benchmarked RNA-Seq analysis workflows [13, 14] , their focus has been primarily on protein-coding genes. Moreover, there is no accepted gold standard pipeline yet which method performs best to quantify expression of lncRNAs. There have been many studies that explore lncRNA expression profile in cancer using publically available RNA-Seq datasets such as those generated by The Cancer Genome Atlas (TCGA), which provide a rich source of lncRNA expression data in large cancer patient populations. Among those studies, the analysis of the lncRNA expression profile of breast cancer samples in TCGA revealed different subtypes of breast cancer and subtype-specific overexpression of HOTAIR [15] . Also, the analysis of 13 cancer types in TCGA revealed highly cancer site-specific lncRNA expression and dysregulation [16] . As the interest in studying lncRNAs in cancer grows, it is necessary to determine which algorithms perform best in lncRNA expression quantification, as it is of uttermost importance to understand the differences and limitations of each of them. and to follow the best practice of RNA-Seq analysis. Because of the lower expression and different properties of lncRNAs to protein coding genes, we hypothesized that the processing and analysis RNA-Seq data for lncRNA expression may be subjected to different technical biases and challenges, and that special considerations may be necessary to optimize the pipeline specifically for lncRNAs. [21] on both simulated and real datasets. Kallisto and Salmon are so-called pseudoalignment methods, as they do not align reads to the reference genome; instead, they assign reads to a set of compatible transcripts. The alignment-free feature makes pseudoalignment methods much faster than alignment-based methods, since the latter requires alignment of the sequencing reads to the genome or transcriptome. While pseudoalignment methods are widely accepted to improve the 9 discordant, indicating that antisense lncRNAs are more susceptible to mis-quantification from alignment-based methods (chi-squared test p-value < 1e-04) ( Figure 4D ). The lncRNAs with fewer transcripts tend to be more discordant. Specifically, when measured by alignment-based methods, over 20% of expressed lncRNAs with only one transcript are discordant, which is more than two times higher compared to those with two transcripts or more (Supplementary Figure   4A) . In terms of the number of exons, lncRNAs with two exons have the highest ratio of discordance (Supplementary Figure 4B) . The fraction of unique kmers (31mers) per lncRNA, i.e., the degree of 'uniqueness', has a greater effect on the performance of alignment-based methods. For lncRNAs with low uniqueness (less than 20% unique sequences,) the mean correlation for HTSeq and featureCounts with ground truth is below 0.3, and the correlation increases as the uniqueness of the lncRNAs increases. Kallisto and Salmon perform well even for lncRNAs with very low uniqueness. However, uniqueness only explains part of the discordance, as there are still considerable number of discordant genes even with high uniqueness (Supplementary Figure 4C) .
Examples of concordant and discordant lncRNAs
Several lncRNAs that were previously linked to cancer are shown in Spearman correlation of TPM between 5% and 30% noise levels. Each point in the boxplot represent one lncRNA. Spearman correlation was calculated across 63 samples. E) Similarity matrix of combinations of tools and noise levels. Each grid in the matrix is the number of times that two entries were clustered in the same group, which is counted from hierarchical clustering of 1,022 expressed lncRNAs. The group number for cutting the hierarchical clustering dendrogram was set as four. In both single gene and method level clustering, Euclidean distance and average linkage were used. PCT, percentage; biasC, bias correction option of the method was used. Tables on the right show the number of discordant lncRNAs for each method.
Supplementary Figure 5 Examples of discordant lncRNAs in cancer.
The lncRNAs that were previously reported to have copy number changes in cancer are shown in the simulated dataset. Heatmap shows the TPM (log transformed) of each method under different noise levels, across 63 samples. Euclidean distance and average linkage were used. 005, 5% noise level; 015, 15% noise level; 030, 30% noise level; biasC, bias correction option of the method was used.
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Supplementary Figure 6 Cancer-site specific lncRNAs lncRNAs in pan-cancer dataset A) Number and B) Heatmap of cancer-site specific lncRNAs. Cancer-site specific lncRNAs are defined as those with median TPM above one in the specific cancer, median TPM below one in other cancer samples, maximum log TPM below one in other cancer samples, and p values from Wilcoxon signed-rank test between groups less than 0.0001. TPM values in this plot were reported by Kallisto. COAD and READ are considered from the same cancer site. Only 184 primary tumor samples and leukemia samples are included in the analysis.
Supplementary Figure 7 CPU time for each tool
CPU time was calculated with 21 samples. Single thread was used. For STAR, RSEM, HTSeq, and featureCounts, default parameters were applied. For Kallisto and Salmon, bootstrap (100 times) or bias correction options were also added. bias, bootstrap (+) and bias correction (+); nobias, bootstrap (+) and bias correction (-); noboot_bias, bootstrap (-) and bias correction (+); noboot_nobias, bootstrap (-) and bias correction (-). The tools suitable for profiling the expression of genes, transcripts, and exons were marked.
Supplementary
1 The tools output transcript-level quantification by default. Gene-level expression is aggregated from transcript-level result using the tximport package. 2 The time of STAR processing was added.Figure 5 
